Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
Esmo 2022 – Galleri’s real-world exhibition disappoints
Grail finds the path for its liquid biopsy less clear than it might have hoped.
Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.